



SARS-CoV-2 Rapid Antigen Test

Enables fast decision-making to help limit further spread

The SARS-CoV-2 Rapid Antigen Test and SARS-CoV-2 Rapid Antigen Test Nasal allow for fast decentralised testing at the point of care, with results available within 15 to 30 minutes. No instrument or specialised equipment is required. They are useful in expanding testing availability into diverse settings outside the laboratory, including rural/remote and low infrastructure areas.¹



These rapid antigen tests are useful for medical or healthcare practitioners to test individuals suspected of COVID-19, or with known or suspected exposure to SARS-CoV-2. They provide a rapid and economical means to help decide if an individual may need to be quarantined/isolated, or whether further testing is needed.²

Main benefits


- » **No analyser** required
- » **Fast results** with a 15 minute turn around time
- » **Prefilled reagents** to ensure simple ease of use, minimal handling steps, and reduced risk of manual errors
- » **Virus inactivation** is achieved in the buffer after 2 minutes
- » **Sample options:** test sample directly from patient; and for NP test, a sample already contained in viral or universal transport media
- » **Storage:** test kits can be stored at room temperature

Getting fast answers is just a few steps away

Performing the SARS-CoV-2 Rapid Antigen Test



Performing the SARS-CoV-2 Rapid Antigen Test Nasal



! Risk of incorrect results. Do not read the test result after 30 min.

Read the test result at 15 - 30 min.

Nasal sampling can help reduce overall patient discomfort, particularly in sensitive individuals such as children, elderly people and/or people with disabilities.

Delivering reliable results at the point of care^{3,4,5}

SARS-CoV-2 Rapid Antigen Test

Sensitivity	95.5% (Ct value ≤ 30; 95% CI: 91.8% - 97.8%)
Specificity	99.2% (95% CI: 98.2% - 99.7%)

SARS-CoV-2 Rapid Antigen Test Nasal

Sensitivity	82.7 % (95 % CI: 75.6 % - 88.4 %)
Specificity	99.1 % (95 % CI: 97.9 % - 99.7 %)

Reference:

1. Subject to the current TGA conditions on inclusion specifically for rapid antigen point-of-care tests. (<https://www.tga.gov.au/applying-tga-assessment-covid-19-test-inclusion-artg>)
2. Refer to the current instructions for use for full information.
3. Compared to an FDA EUA authorised laboratory based real time reverse transcription PCR test.
4. SARS-CoV-2 Rapid Antigen Test Product Information AU V3.0.
5. SARS-CoV-2 Rapid Antigen Test Nasal Product Information AU V2.0.


Assay Characteristics

Test type	Qualitative - rapid chromatographic immunoassay
Sample type	<ul style="list-style-type: none"> ▪ Direct collection from patient ▪ Nasopharyngeal: Sample contained in VTM/UTM
Target antigen	Nucleocapsid (N)
Time to result	15 minutes
Time to read result	Between 15 & 30 minutes
Storage temperature	Store the kit at 2-30°C / 36-86°F out of direct sunlight. Do not freeze.
Stability	NP: Up to 1 hr (15-25°C) or 4 hr (2-8°C) / Nasal: Up to 4 hr (15-25°C or 2-8°C)
Registration	Included on ARTG 352250

Understanding the results when you need to know



C Control, test is valid
T Antigens specific to SARS-CoV-2 detected



In case of a positive result, a coloured test line T appears in the lower section of the result window.

In case of a negative result, only the control line C appears.

If no control line C is visible, the test is always invalid.

Test Description	Quantity Per Kit	Catalogue Number
SARS-CoV-2 Rapid Antigen Test	25	09327592023, 09327592043
SARS-CoV-2 Rapid Antigen Control Kit	10 sets of positive and negative	09338322190
SARS-CoV-2 Rapid Antigen Test Nasal*	25	09365397043
SARS-CoV-2 Antigen Control Swab	10 each of positive and negative controls	09396276043

